爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil+indapamiid - õhukese polümeerikattega tablett - 5mg+1,25mg 500tk; 5mg+1,25mg 100tk; 5mg+1,25mg 14tk; 5mg+1,25mg 28tk; 5mg+1,25mg 20tk; 5mg+1,25mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil+indapamiid - õhukese polümeerikattega tablett - 2,5mg+0,625mg 14tk; 2,5mg+0,625mg 90tk; 2,5mg+0,625mg 28tk; 2,5mg+0,625mg 60tk; 2,5mg+0,625mg 56tk; 2,5mg+0,625mg 500tk; 2,5mg+0,625mg 20tk; 2,5mg+0,625mg 50tk; 2,5mg+0,625mg 100tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

vitaflo - l-arginiin - suukaudne pulber - 2000mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil+indapamiid - õhukese polümeerikattega tablett - 2,5mg+0,625mg 20tk; 2,5mg+0,625mg 14tk; 2,5mg+0,625mg 30tk; 2,5mg+0,625mg 90tk; 2,5mg+0,625mg 500tk; 2,5mg+0,625mg 56tk; 2,5mg+0,625mg 60tk; 2,5mg+0,625mg 100tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil - suus dispergeeruv tablett - 10mg 500tk; 10mg 120tk; 10mg 90tk; 10mg 30tk; 10mg 50tk; 10mg 20tk; 10mg 100tk; 10mg 5tk; 10mg 60tk; 10mg 14tk; 10mg 10tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 30tk; 10mg 10tk; 10mg 50tk; 10mg 60tk; 10mg 5tk; 10mg 28tk; 10mg 120tk; 10mg 100tk; 10mg 84tk; 10mg 500tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil - õhukese polümeerikattega tablett - 5mg 100tk; 5mg 10tk; 5mg 90tk; 5mg 500tk; 5mg 50tk; 5mg 28tk; 5mg 60tk; 5mg 84tk; 5mg 14tk; 5mg 120tk; 5mg 20tk; 5mg 5tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil - suus dispergeeruv tablett - 5mg 20tk; 5mg 100tk; 5mg 30tk; 5mg 90tk; 5mg 14tk; 5mg 10tk; 5mg 50tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

les laboratoires servier - perindopriil - suus dispergeeruv tablett - 2,5mg 120tk; 2,5mg 20tk; 2,5mg 14tk; 2,5mg 60tk; 2,5mg 50tk; 2,5mg 5tk; 2,5mg 10tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.